---
title: "Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | ZBIO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286900519.md"
description: "Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | ZBIO Stock News"
datetime: "2026-05-19T03:05:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286900519.md)
  - [en](https://longbridge.com/en/news/286900519.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286900519.md)
---

# Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | ZBIO Stock News

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | ZBIO Stock News

### Related Stocks

- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)

## Related News & Research

- [Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target](https://longbridge.com/en/news/286916856.md)
- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)
- [Zenas BioPharma Highlights Strong Q1 Progress and Financing](https://longbridge.com/en/news/286243392.md)
- [ZenaTech Advances Three ZenaDrone Defense Platforms Through Blue UAS Certification Pathway | ZENA Stock News](https://longbridge.com/en/news/286910480.md)
- [Tuesday 5/19 Insider Buying Report: ZBIO, ICFI](https://longbridge.com/en/news/286954937.md)